List of Emerphed drug patents

Emerphed is owned by Nexus Pharms.

Emerphed contains Ephedrine Sulfate.

Emerphed has a total of 5 drug patents out of which 0 drug patents have expired.

Emerphed was authorised for market use on 17 April, 2020.

Emerphed is available in solution;intravenous dosage forms.

Emerphed can be used as use of ephedrine sulfate for treating hypotension.

The generics of Emerphed are possible to be released after 16 May, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090278 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11241400 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11464752 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11478436 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11571398 NEXUS PHARMS NA
May, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 17 April, 2020

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of EMERPHED before it's patent expiration?
More Information on Dosage

EMERPHED family patents

7

United States

1

Japan

1

Korea, Republic of

1

Israel

1

Australia

1

Canada

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in